title: Ex vivo expanded mobilized peripheral blood CD34+ cells accelerate haematological recovery in a baboon model of autologous transplantation.
abstract: To address the value of ex vivo expanded haematopoietic cells for shortening cytopenia in autologous haematopoietic transplantation, we designed an ex vivo expansion protocol based on a cocktail of early acting cytokines and short-term culture and tested it in a baboon model. Expansion involved enriched CD34+ peripheral blood haematopoietic cells cultured for 6 d with a combination of FLT3-L, stem cell factor (SCF), thrombopoietin (TPO) and interleukin (IL)-3 (50 ng/ml each); CD34+ cells, granulocyte-macrophage colony-forming units (GM-CFU) and megakaryocytic colony-forming units (MK-CFU) were amplified, respectively, 10.5-, 20.5- and 17.9-fold. Baboons were submitted to a myeloablative regimen consisting of cyclophosphamide plus total body irradiation (TBI; 6 Gy) and were then grafted with either 2 x 106/kg unmanipulated CD34+ cells (control group, n = 4) or cells cultured from 2 x 106/kg CD34+ cells (expansion group, n = 4). No cytokines were administered after transplantation. All the animals engrafted. The mean times to white blood cell (WBC), granulocyte and platelet recovery were significantly shorter in the expansion group than in the control group: WBC (> 1 x 109/l) and neutrophil (> 0.5 x 109/l) recovery occurred on days 8 (range 6-9) and 9 (range 6-11), respectively, compared with days 12 (range 10-15) and 14 (range 11-16); platelets recovered (> 20 x 109/l) on day 9 (range 7-12) compared with day 13 (range 11-15) in the control group (P < 0.05). No toxicity was observed after reinfusion. No secondary hypoplasia was observed during more than 12 months of follow-up. Functions of both neutrophils and platelets produced from expanded cells were normal in terms of oxidative metabolism, chemotaxis and the bleeding time. This study shows that in comparison with unmanipulated cells peripheral blood haematopoietic cells expanded from similar doses of CD34+ cells, under the conditions defined here, accelerated both neutrophil and platelet recovery without impairing long-term haematopoiesis.
authors.affiliation: INSERM U 362, Institut Gustave Roussy, PR1, 94800 Villejuif, France.
authors.forename: F
authors.initials: F
authors.lastname: Norol
authors.forename: M
authors.initials: M
authors.lastname: Drouet
authors.forename: J
authors.initials: J
authors.lastname: Mathieu
authors.forename: N
authors.initials: N
authors.lastname: Debili
authors.forename: H
authors.initials: H
authors.lastname: Jouault
authors.forename: N
authors.initials: N
authors.lastname: Grenier
authors.forename: A
authors.initials: A
authors.lastname: Laplanche
authors.forename: W
authors.initials: W
authors.lastname: Vainchenker
authors.forename: F
authors.initials: F
authors.lastname: Hérodin
mesh_terms: D000818:Animals; D018952:Antigens, CD34 / Q000276:immunology; D018929:Cell Culture Techniques; D015925:Cryopreservation; D004195:Disease Models, Animal; D005434:Flow Cytometry; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D007377:Interleukin-3 / Q000494:pharmacology; D007958:Leukocyte Count; D008297:Male; D008565:Membrane Proteins / Q000494:pharmacology; D010215:Papio; D010976:Platelet Count; D011994:Recombinant Proteins / Q000494:pharmacology; D019089:Stem Cell Factor / Q000494:pharmacology; D013234:Stem Cells / Q000187:drug effects / Q000276:immunology; D013926:Thrombopoietin / Q000494:pharmacology; D014182:Transplantation, Autologous
chemical_list: D018952:Antigens, CD34; D007377:Interleukin-3; D008565:Membrane Proteins; D011994:Recombinant Proteins; D019089:Stem Cell Factor; C084881:flt3 ligand protein; D013926:Thrombopoietin